Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Recurrent NSCLC After Prior EGFR TKI Therapy
NCT00694603Phase 2Terminated
- Sponsor
- Lecia V. Sequist
- Start
- Sep 2006
- Primary completion
- Sep 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Lecia V. Sequist. Started Sep 2006; status: terminated.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00694603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694603.